MedTrace Logo

Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide

NCT06041893 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-12-03

No results posted yet for this study

Summary

Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.

Conditions

  • Haploidentical Hematopoietic Stem Cell Transplantation

Interventions

DRUG

ATG-LDPTCy

antithymocyte globulin with low dose post-transplant cyclophosphamide

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Keon Hee Yoo, Professor · Samsung Medical Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-29
Primary Completion
2025-07-05
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06041893 on ClinicalTrials.gov